FeesSafety
Pluang+

Eli Lilly stock jumps 4% on EU nod for oral obesity pill Foundayo, outpacing peers Amgen and Novo Nordisk.

Market News
20 Oct 2026, 19:55 WIB
24/7 Wall Street
View Source
Bullish
Eli Lilly stock jumps 4% on EU nod for oral obesity pill Foundayo, outpacing peers Amgen and Novo Nordisk.

Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight management and diabetes, unlike the current EU-approved competitor from Novo Nordisk. Amgen and Novo Nordisk stocks also rose but lagged behind Lilly's gains. The next step is the European Commission's final decision, which will determine Foundayo's market entry and competitive position in Europe.

Eli Lilly's stock is up 4.18% on Pluang, trading at USD 1,292.22 with a market cap of $1.11T as of Oct 21, 2026 00:01 WIB. Amgen and Novo Nordisk also show gains, with Amgen up 2.27% and Novo Nordisk up 1.95% at the same time.

More News (LLY)

Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.

Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.

Eli Lilly dominates the obesity drug market with its approved treatments Zepbound and Foundayo, showing strong sales growth—Zepbound's revenue rose 49% to $5.4 billion in Q3 2026. The company’s pipeline includes promising candidates like retatrutide ...

Market News
Bullish
1 hour ago
Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly remains a leader in the obesity drug market with its approved products Zepbound and Foundayo showing strong sales growth. New pipeline candidates like retatrutide and EloraTZP have demonstrated greater weight loss in trials, positioning the...

Market News
Bullish
6 hours ago
Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly has seen its revenue soar thanks to its dominance in the weight loss drug market, with products like Mounjaro and Zepbound contributing to a 39% revenue increase to over $24 billion recently. The company leads in GLP-1 drugs, which regulate...

Market News
Bullish
15 hours ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and showing improved health markers. This success could lead to lab...

Company Fundamentals
Bullish
1 day ago
Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk lost its lead in the GLP-1 weight-loss shot market to Eli Lilly due to supply issues but has rebounded strongly with its new GLP-1 pill, which captured 80% of new oral treatment patients in Q3 2026. The company is shifting to a volume-dr...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App